Uncategorized

Genexine announced the publication of an abstract of its phase 2 clinical trial on triple combination neoadjuvant therapy for HNSCC in the ASCO.

Invitae, a leading medical genetics company, announced that Chief Financial Officer Yafei Wen is resigning to pursue other opportunities, effective June 30, 2023.

Ascentage Pharma announced that 4 of its abstracts were selected for presentations at the 2023 American Society of Clinical Oncology Annual Meeting.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the 2023 American Association of Clinical Oncology annual meeting to be held in Chicago, IL.

Antengene Corporation Limited announced that the latest results from the Phase I/II TORCH-2 study will be presented as a poster at the 2023 American Society for Clinical Oncology Annual Meeting taking place from June 2nd to 6th, 2023 at the McCormick Place Convention Center in Chicago, IL.

Sobre el secreto de los buenos especialistas y su capacidad comunicativa

The Massachusetts-based biopharma became the second company this week to drop its amyotrophic lateral sclerosis hopeful after it failed to elicit significant improvement compared with placebo. 

The Kaiser Family Foundation survey found many enrollees weren’t sure whether states are now allowed to remove people from the program, and 27% wouldn’t know where to look for coverage if they ineligible for Medicaid.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”) today announced that its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer, has enrolled 134 patients, representing more than 50% of the total planned enrollment for the study.

The decision to replace board chair John Thompson could change the company’s course as it decides whether to divest liquid biopsy company Grail.